DexCom has a lower P/E than the aggregate P/E of 56.86 of the Health Care Equipment & Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also ...
Wall Street expects a year-over-year increase in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...
Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose ...
DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...
DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc., the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO ...
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...
SAN DIEGO, January 12, 2026--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of ...
It has had strong momentum since November, but there is still plenty of upside left.
9don MSN
Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments
DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results